FDA blocked melanoma drug as confusion reigned under Makary

The FDA blocked a melanoma drug due to confusion under Makary's leadership. A clinical trial showed that a third of patients had tumors shrink while taking RP1, a genetically engineered treatment. The trial results were promising despite the FDA blockage.